Hybrid model combining in-house and joint development businesses
First written in FY2024. 3 of 7 entries say "Restated". Latest entry: 2026-08-14.
2 other companies' latest entry also says "Restated".
- FY2025AdvancedAnnual report
「In addition, during the current fiscal year, we began a business in which we propose drug targets, obtain hit compounds, and then develop programs together with major pharmaceutical companies.」
In addition to the traditional model combining proprietary development with partnered development based on pharmaceutical-company targets, the company began during the current fiscal year a form of partnered development in which it handles target proposals and hit compound identification. - FY2025-H1RestatedAnnual report
「The company conducts proprietary development, in which it selects drug targets and identifies development compounds, and partnered development, in which it identifies and licenses hit compounds, lead compounds, or clinical candidates against drug targets held by pharmaceutical companies.」
There has been no material change to the business model combining proprietary development and partnered development. - FY2024First statedAnnual report
「By leveraging PepMetics technology and combining two revenue models, proprietary development, which is high-risk and high-return, and partnered development, which offers stable and early monetization, the company is able to pursue both stable and substantial returns.」
The model combines a business in which the company selects targets itself with joint research on targets selected by pharmaceutical companies, pursued in parallel.